How I Cured My Akathisia: Treatments That Worked

Akathisia, that relentless inner restlessness and compulsion to move, has several evidence-backed treatments, though no single approach works for everyone. The strategies with the strongest track records include beta-blockers like propranolol, low-dose mirtazapine, benzodiazepines, high-dose vitamin B6, and, when possible, reducing or switching the medication that triggered the problem. The frustrating reality is that akathisia treatment often requires trying more than one of these options, sometimes in combination, before finding relief.

Why Akathisia Happens and Why That Matters for Treatment

Understanding the basic mechanism helps explain why certain treatments work and others do not. Akathisia is most commonly triggered by medications that block dopamine receptors in the brain, particularly the D2 subtype. When drugs occupy too many of these receptors in a brain region called the striatum, the result can be involuntary movement problems. The risk climbs sharply once roughly 80% of D2 receptors are blocked.¹ Antipsychotic medications are the most frequent culprits, but the phenomenon is not limited to D2 blockade alone. PET imaging studies in healthy volunteers showed that selectively blocking either D1 or D2 dopamine receptors could produce akathisia, with the two receptor types acting together in a way that amplifies the problem.²

This dopamine-centered picture is only part of the story, though. Serotonin pathways, norepinephrine signaling, and possibly iron-dependent processes in the brain all seem to play supporting roles. That is why treatments targeting different neurotransmitter systems can each provide some degree of relief, and why a purely dopamine-focused approach sometimes falls short.

The First Move Is Often the Simplest

Before adding a new medication to counteract akathisia, clinicians typically look at whether the triggering drug can be reduced in dose or swapped for a different one. Clinical guidelines list dose reduction and antipsychotic switching among the strategies with adequate evidence for managing akathisia.³ This makes intuitive sense: if the problem stems from too many dopamine receptors being blocked, easing up on the blocking agent should help. In practice, though, dose reduction is not always possible without the underlying psychiatric condition flaring up, and switching medications introduces its own period of uncertainty. For people who cannot change their antipsychotic regimen, the add-on treatments described below become the main line of defense.

Beta-Blockers, Especially Propranolol

Propranolol is probably the most widely used medication specifically for akathisia, and it has been a go-to option since the 1980s. In one of the earlier open trials, all 14 patients with neuroleptic-induced akathisia showed substantial improvement on propranolol, with nine achieving complete remission. The doses were modest, typically between 30 and 80 mg per day, and relief often came within 24 hours.⁴ Later controlled trials confirmed this benefit, and propranolol remains one of the treatments with the best-established evidence base for akathisia.

The mechanism is not entirely understood. Propranolol is a nonselective beta-blocker, meaning it acts on beta-adrenergic receptors throughout the body, and it also crosses into the brain. One theory is that it calms the noradrenergic overactivity that accompanies dopamine blockade. Whatever the explanation, the practical takeaway is that propranolol tends to work quickly and at relatively low doses. Side effects like low blood pressure, fatigue, and slowed heart rate are possible but are generally mild at the doses used for akathisia. People with asthma or certain heart conditions should avoid it.

Low-Dose Mirtazapine

Over the past two decades, a growing body of evidence has pointed to medications that block a specific serotonin receptor, the 5-HT2A receptor, as a promising class of anti-akathisia treatments. Among these, low-dose mirtazapine, typically 7.5 mg or 15 mg taken once daily, has shown the most compelling results.⁵ Mirtazapine is technically an antidepressant, but at these low doses its main effects are sedation and 5-HT2A blockade rather than its antidepressant action, which kicks in at higher doses.⁶

One case report documented mirtazapine resolving severe, treatment-resistant akathisia that had not responded to other interventions. Other 5-HT2A antagonists such as cyproheptadine, trazodone, and mianserin have also shown benefit in smaller studies, but mirtazapine has accumulated the strongest evidence so far.⁵ The main trade-off is sedation and potential weight gain, both common side effects of mirtazapine even at low doses. For someone already struggling with insomnia from akathisia’s relentless restlessness, the sedation can feel like a bonus rather than a drawback.

Benzodiazepines

Clonazepam and other benzodiazepines are sometimes used when akathisia does not respond to beta-blockers or when anxiety is a prominent component. A Cochrane review found that clonazepam reduced akathisia symptoms compared with placebo over one to two weeks, though the evidence came from small trials involving only 26 patients total.⁷ The review’s cautious conclusion was that benzodiazepines “may” reduce symptoms of antipsychotic-induced acute akathisia.

The evidence here is thinner than for propranolol or mirtazapine, and benzodiazepines carry well-known risks of dependence and cognitive dulling with long-term use. Most clinicians reserve them for short-term relief or for cases that have not responded to other options. When they work, though, the relief can be dramatic and fast, and they address the agonizing anxiety component that often accompanies akathisia.

High-Dose Vitamin B6

This one surprises many people. Vitamin B6, at high doses far above typical dietary supplementation, has shown genuine promise in controlled trials. In a randomized, double-blind study, patients receiving vitamin B6 showed significantly greater improvement than those on placebo across subjective awareness of restlessness, distress, and global akathisia scores. Eighty percent of patients in the B6 group experienced a meaningful reduction in symptoms, compared with 30% on placebo.⁸

A separate pilot trial directly comparing vitamin B6 to propranolol found no significant difference between the two, meaning B6 performed about as well as the established standard treatment.⁹ That comparison trial also found no significant difference between high and low doses of B6, which complicates dose recommendations. The researchers speculated that B6’s benefit comes from its involvement in multiple neurotransmitter pathways, including dopamine and serotonin synthesis. A word of caution: the doses used in these trials (typically 600 mg to 1200 mg daily) are far beyond the recommended daily allowance. Long-term use of very high-dose B6 can cause peripheral neuropathy, a kind of nerve damage causing numbness and tingling in the hands and feet. This makes B6 more suitable as a time-limited treatment than an indefinite one, and it should be discussed with a prescriber.

Anticholinergic Medications

Drugs like benztropine (Cogentin) and trihexyphenidyl are frequently prescribed for other movement side effects of antipsychotics, such as muscle stiffness and tremor. For akathisia specifically, the evidence is weaker and more mixed. In a small double-blind crossover study of five patients with tardive akathisia, intravenous benztropine produced only marginally significant improvement, while propranolol was clearly better.¹⁰

Clinical guidelines still list anticholinergics among the options for akathisia management, partly because they may help when akathisia coexists with other movement symptoms like parkinsonism.³ On their own, though, anticholinergics are generally considered a second-tier choice for akathisia. They also carry side effects like dry mouth, constipation, blurred vision, and, at higher doses, cognitive impairment, which limits their appeal.

Should You Get Your Iron Levels Checked?

The relationship between iron and akathisia has attracted research attention for decades, partly because iron is essential for dopamine synthesis in the brain. A systematic review and meta-analysis of cross-sectional studies found that patients with akathisia tended to have lower iron levels, and lower ferritin levels in one statistical model, though the ferritin finding was not consistent across different analytical approaches.¹¹

An earlier study found that patients with acute akathisia had somewhat lower ferritin levels than those without it, but the ferritin levels were still within the normal range, and the difference was small enough that the researchers concluded iron deficiency plays only a minor role in acute akathisia.¹² In short, having your iron status checked is reasonable and easy, and correcting a genuine deficiency could help, but iron supplementation on its own is unlikely to resolve moderate or severe akathisia. Think of it as closing a potential contributing factor rather than a standalone cure.

When Antidepressants Are the Trigger

Akathisia is not exclusively an antipsychotic problem. SSRIs and SNRIs, the most commonly prescribed antidepressant classes, can also cause it. A study evaluating nearly 200 patients on these medications found akathisia in a full quarter of them, making it far from rare. The risk was higher in younger patients and in smokers.¹³

SSRI-induced akathisia presents a particular clinical puzzle. If your akathisia is caused by an antidepressant and you add mirtazapine to treat the akathisia, you are now on two medications affecting serotonin, which requires careful monitoring. Beta-blockers may be a cleaner option in this scenario since they work through an entirely different pathway. The more fundamental problem is recognition: antidepressant-induced akathisia is widely described as underdiagnosed. The inner restlessness, agitation, and inability to sit still can easily be mistaken for worsening anxiety or depression, leading a clinician to increase the very medication causing the problem. If you started or increased an SSRI or SNRI shortly before the restlessness began, that timing is a critical clue worth bringing up with your prescriber.

The Difference Between Akathisia, Anxiety, and Restless Legs

One reason akathisia goes untreated for so long is that it mimics other conditions. The subjective experience, a crawling inner discomfort and overwhelming need to move, overlaps significantly with restless legs syndrome and generalized anxiety disorder. Research has noted that akathisia is characterized by restlessness and crawling sensations similar to restless legs syndrome, with lower limb involvement common in both.¹⁴

The distinguishing features are subtle but important. Restless legs syndrome typically worsens at rest and in the evening, and responds to dopamine-enhancing medications. Akathisia is tied to a medication’s presence in your system and responds to the treatments described above. Generalized anxiety involves worry and tension but rarely the same compulsion to pace, rock, or shift weight from foot to foot. When clinicians use structured assessment tools like the Barnes Akathisia Rating Scale, they can distinguish these conditions more reliably, but in a rushed appointment the overlap can easily lead to misdiagnosis. If you suspect akathisia, explicitly mentioning the specific medications you take and the timeline of symptom onset is the most useful thing you can communicate to your doctor.

Why Treating Akathisia Urgently Matters

Akathisia is not just uncomfortable. It is associated with significant psychiatric consequences, including a troubling link to suicidal behavior. In one study of 68 patients treated with antipsychotic medications, roughly a third developed akathisia. Those with akathisia scored significantly higher on measures of suicidal behavior, depersonalization, and agitation. The subjective experience of akathisia, the inner torment that patients describe, was specifically associated with suicidal behavior even when objective signs of restlessness were not prominent.¹⁵

This connection between akathisia and suicidality underscores why the condition deserves urgent attention rather than a wait-and-see approach. The inner distress of akathisia can be so unbearable that patients discontinue their psychiatric medications entirely, which carries its own serious risks. Effective treatment of akathisia is not a luxury; it often determines whether someone stays on a medication regimen that keeps their underlying condition stable.

Why Some People Are More Vulnerable Than Others

Genetics helps explain why two patients on the same antipsychotic at the same dose can have wildly different experiences with akathisia. The CYP2D6 gene, which produces an enzyme responsible for metabolizing many psychiatric medications, comes in dozens of variants. Some people carry variants that make them poor metabolizers, meaning drugs linger in their system at higher concentrations for longer. A systematic review found that poor or intermediate metabolizers had roughly two to five times the odds of developing movement side effects compared with normal metabolizers. In studies of haloperidol specifically, between 40% and 80% of poor metabolizers developed clinically relevant movement problems, compared with just 12% to 30% of normal metabolizers.¹⁶

Separately, a study examining cases of antidepressant-induced akathisia found that variant CYP450 alleles were more common in people who developed akathisia than in a comparison group of primary care patients. Nearly all of the affected individuals also used interacting drugs, herbal supplements, or other substances that further impaired their drug metabolism.¹⁷ Pharmacogenomic testing, a simple cheek swab that maps your CYP450 enzyme profile, is increasingly available and can inform medication choices. If you have experienced akathisia repeatedly across different medications, this testing may reveal an underlying metabolic reason and help guide future prescribing.

Medications That Can Make Akathisia Worse

While searching for relief, it is worth knowing about medications that can paradoxically worsen akathisia or introduce it anew. VMAT2 inhibitors such as valbenazine and deutetrabenazine, which are prescribed for tardive dyskinesia, another movement disorder caused by antipsychotics, list akathisia among their known side effects. Combining these agents with antipsychotic medications further raises the risk of akathisia and other movement problems.¹⁸ This creates a frustrating clinical scenario for someone with both tardive dyskinesia and akathisia: a medication intended to treat one movement disorder may aggravate the other.

Drug interactions also deserve attention. Adding a medication that inhibits CYP2D6, such as fluoxetine (Prozac) or paroxetine (Paxil), on top of an antipsychotic can effectively increase the antipsychotic’s blood levels even without changing the dose. The result is the same as a dose increase: more dopamine receptor blockade and higher akathisia risk. If your akathisia appeared shortly after adding a new medication to your regimen, even one not typically associated with movement problems, the interaction angle is worth investigating.

Practical Steps When You Are in the Middle of It

If you are actively experiencing akathisia, a few practical points may help while you work with your prescriber on a pharmacological solution. Movement itself, walking, stretching, rocking, provides temporary relief for most people and is not something to feel embarrassed about. Reducing caffeine intake can help since stimulants tend to amplify the restlessness. Timing matters too: if your akathisia peaks at predictable times of day relative to when you take your medication, that information helps your prescriber adjust the dosing schedule or choose the right add-on treatment.

Keeping a brief daily log of your symptom intensity, when it peaks, what makes it better or worse, and which treatments you have tried gives your clinician far more useful information than a general statement of “I feel restless.” The Barnes Akathisia Rating Scale is the standard clinical tool for this, and while your doctor administers it formally, understanding its components can help you communicate more effectively. It separates the subjective inner restlessness, the observable motor restlessness, and overall severity, each of which can respond differently to different treatments. Someone whose main burden is the inner torment with relatively little visible movement may respond differently than someone who is visibly pacing and rocking but reports less subjective distress.

Finding the right treatment for akathisia often takes persistence, and the trial-and-error process can feel demoralizing when you are already suffering. But the evidence base, while imperfect, does support several genuinely effective options. Propranolol works quickly and reliably for many people. Low-dose mirtazapine offers a strong alternative, particularly for treatment-resistant cases. High-dose vitamin B6 provides a surprisingly well-supported option with a different side effect profile. And for some people, the answer turns out to be as straightforward as lowering a dose or switching to a medication that occupies fewer dopamine receptors. The key is recognizing akathisia for what it is, not mistaking it for anxiety or agitation, and pursuing treatment aggressively rather than enduring it as an unavoidable cost of psychiatric medication.